These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6208043)

  • 1. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation.
    Sonsalla PK; Gibb JW; Hanson GR
    Eur J Pharmacol; 1984 Oct; 105(1-2):185-7. PubMed ID: 6208043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
    Starr BS; Starr MS; Kilpatrick IC
    Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.
    Oblin A; Zivkovic B; Bartholini G
    Brain Res; 1987 Sep; 421(1-2):387-90. PubMed ID: 2446703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release?
    Starr M
    J Neurochem; 1987 Oct; 49(4):1042-9. PubMed ID: 2957468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
    Merchant KM; Bush LG; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK; McGinty JF; Hong JS
    Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of dopaminergic influence on striatal-nigral neurotensin systems.
    Letter AA; Matsuda LA; Merchant KM; Gibb JW; Hanson GR
    Brain Res; 1987 Sep; 422(1):200-3. PubMed ID: 3119151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotation following intranigral injections of a selective D1 or a selective D2 dopamine receptor agonist in rats.
    Asin KE; Montana WE
    Pharmacol Biochem Behav; 1988 Jan; 29(1):89-92. PubMed ID: 3258427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.
    Molloy AG; Waddington JL
    Br J Pharmacol; 1988 Oct; 95(2):335-42. PubMed ID: 2906555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
    Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
    Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative radioimmunocytochemical evidence that haloperidol and SCH 23390 induce opposite changes in substance P levels of rat substantia nigra.
    Cruz CJ; Beckstead RM
    Brain Res; 1988 Aug; 457(1):29-43. PubMed ID: 2458801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of dopaminergic terminal excitability by D1 selective agents.
    Diana M; Young SJ; Groves PM
    Neuropharmacology; 1989 Jan; 28(1):99-101. PubMed ID: 2522599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 synthesis-modulating receptors are present in the striatum of the guinea pig.
    Johnson EA; Tsai CE; Lucci J; Harrison-Shahan Y; Azzaro AJ
    Neuropharmacology; 1992 Jan; 31(1):95-101. PubMed ID: 1347405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.
    Rouillard C; Bédard P; Falardeau P; Di Paolo T
    Eur J Pharmacol; 1988 Nov; 157(2-3):125-33. PubMed ID: 2975996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.